Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma

Published:2023-02-24 Issue:2 Volume:18 Page:247-255
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Lee Nuri,Lee Jae Lyun,Lee Ju-Yeun^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-023-00951-z.pdf

Reference25 articles.

1. National Comprehensive Cancer Network. Kidney cancer (Version 1.2022). Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed 7 Sept 2021.

2. Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11(2):172–91. https://doi.org/10.1016/j.ejcsup.2013.07.016.

3. Kirino S, Tsuchiya K, Kurosaki M, et al. Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE. 2020;15(4): e0231828. https://doi.org/10.1371/journal.pone.0231828.

4. Manz KM, Fenchel K, Eilers A, Morgan J, Wittling K, Dempke WCM. Efficacy and safety of approved first-line tyrosine kinase inhibitor treatments in metastatic renal cell carcinoma: a network meta-analysis. Adv Ther. 2020;37(2):730–44. https://doi.org/10.1007/s12325-019-01167-2.

5. Gan CL, Dudani S, Wells JC, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Med. 2021;10(4):1212–21. https://doi.org/10.1002/cam4.3717.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sorafenib safety evaluation: Real-world analysis of adverse events from the FAERS database;Heliyon;2024-09

2. The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis;BJC Reports;2024-08-13

3. A commentary on “Risk factors for incident venous thromboembolism in patients with renal tumor and inferior vena cava tumor thrombus: a retrospective case–control study”;International Journal of Surgery;2024-03-18

4. Cardiovascular disease burden in patients with urological cancers: The new discipline of uro‐cardio‐oncology;Cancer Innovation;2024-02-05

5. Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer;JAMA Network Open;2023-11-29